Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial

Abhinav Sharma, Andrew P Ambrosy, Adam D DeVore, Kenneth B Margulies, Steven E McNulty, Robert J Mentz, Adrian F Hernandez, Gary Michael Felker, Lauren B Cooper, Anuradha Lala, Justin Vader, John D Groake, Barry A Borlaug, Eric J Velazquez, Abhinav Sharma, Andrew P Ambrosy, Adam D DeVore, Kenneth B Margulies, Steven E McNulty, Robert J Mentz, Adrian F Hernandez, Gary Michael Felker, Lauren B Cooper, Anuradha Lala, Justin Vader, John D Groake, Barry A Borlaug, Eric J Velazquez

Abstract

Aims: Obesity is present in up to 45% of patients with heart failure (HF). Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor antagonist, facilitates weight loss in obese patients. The efficacy of liraglutide as a weight loss agent among patients with HF and reduced ejection fraction (HFrEF) and a recent acute HF hospitalization remains unknown.

Methods and results: The Functional Impact of GLP-1 for Heart Failure Treatment study randomized 300 patients with HFrEF (ejection fraction ≤ 40%), both with and without diabetes and a recent HF hospitalization to liraglutide or placebo. The primary outcome for this post hoc analysis was the change in weight from baseline to last study visit. We conducted an 'on-treatment' analysis of patients with at least one follow-up visit on study drug (123 on liraglutide and 124 on placebo). The median age was 61 years, 21% were female, and 69% of patients had New York Heart Association functional Class III or IV symptoms. The median ejection fraction was 25% (25th, 75th percentile 19-32%). Liraglutide use was associated with a significant weight reduction [liraglutide -1.00 lbs vs. placebo 2.00 lbs; treatment difference -4.10 lbs; 95% confidence interval (CI) -7.94, -0.25; P = 0.0367; percentage treatment difference -2.07%, 95% CI -3.86, -0.28; P = 0.0237]. Similar results were seen after multivariable adjustments. Liraglutide also significantly reduced triglyceride levels (liraglutide 7.5 mg/dL vs. placebo 12.0 mg/dL; treatment difference -33.1 mg/dL; 95% CI -60.7, -5.6; P = 0.019).

Conclusions: Liraglutide is an efficacious weight loss agent in patients with HFrEF. These findings will require further exploration in a well-powered cardiovascular outcomes trial.

Trial registration: ClinicalTrials.gov NCT01800968.

Keywords: Diabetes; Heart failure; Liraglutide; Weight loss.

© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

Figures

Figure 1
Figure 1
Weight change frequencies associated with treatment.

References

    1. Horwich TB, Broderick S, Chen L, McCullough PA, Strzelczyk T, Kitzman DW, Fletcher G, Safford RE, Ewald G, Fine LJ, Ellis SJ, Fonarow GC. Relation among body mass index, exercise training, and outcomes in chronic systolic heart failure. Am J Cardiol 2011; 108: 1754–1759.
    1. Joyce E, Lala A, Stevens SR, Cooper LB, AbouEzzeddine OF , Groarke JD, Grodin JL, Braunwald E, Anstrom KJ, Redfield MM, Stevenson LW. Prevalence, profile, and prognosis of severe obesity in contemporary hospitalized heart failure trial populations. JACC Heart Fail 2016; 4: 923–931.
    1. Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjoth TV, Andreasen AH, Jensen CB, DeFronzo RA. Efficacy of liraglutide for weight loss among patients with type 2 diabetes. JAMA 2015; 314: 687–699.
    1. Pi‐Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DCW, le Roux CW, Violante R, Jensen CB, Wilding JPH. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015; 373: 11–22.
    1. (20 March 2017).
    1. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, COle R, Mann DL, Whellan DJ, Kiernan MS, Felker GM, McNulty SE, Anstrom KJ, Shah MR, Braunwald E, Cappola TP. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction. JAMA 2016; 316: 500–508.
    1. Margulies KB, Anstrom KJ, Hernandez AF, Redfield MM, Shah MR, Braunwald E, Cappola TP. GLP‐1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP‐1 for heart failure treatment study. Circ Heart Fail 2014; 7: 673–679.
    1. Lala A, McNulty SE, Mentz RJ, Dunlay S, Vader JM, AbouEzzeddine OF, DeVore AD, Khazanie P, Redfield MM, Goldsmith SR, Bart BA, Anstrom KJ, Felker GM, Hernandez AF, Steven LW. Relief and recurrence of congestion during and after hospitalization for acute heart failure. Circ Heart Fail 2015; 8: 741–748.
    1. Marso SP, Daniels GH, Brown‐Frandsen K, Kristensen P, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311–322.
    1. Cefalu WT, Bakris G, Blonde L. Standards of medical care in diabetes. Diabetes Care 2015; 38: 1177–1180.
    1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Jannuzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff B. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147–e239.
    1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez‐Juanatey JR, Harjola V, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail 2016; 18: 891–975.
    1. Sharma A, Demissei BG, Tromp J, Hillege HL, Cleland JG, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Davison BA, Givertz MM, Bloomfield DM, Dittrich H, van Veldhuisen DJ, Cotter G, Ezekowitz JA, Khan MA, Voors AA. A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure. Eur J Heart Fail 2017; 19: 1310–1320.
    1. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373: 232–242.
    1. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317–1326.
    1. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327–1335.
    1. Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hanselmann A, Nilsson B, Moller JE, Hjort J, Rasmussen J, Boesgaard TW, Schou M, Videbaek L, Gustafsson I, Flyvbjerg A, Wiggers H, Tarnow L. Effect of liraglutide, a glucagon‐like peptide‐1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double‐blind, randomised, placebo‐controlled trial. Eur J Heart Fail 2016; 19: 69–77.
    1. Sharma A, Bhatt DL, Calvo G, Brown NJ, Zannad F, Mentz RJ. Heart failure event definitions in drug trials in patients with type 2 diabetes. Lancet Diabetes Endocrinol 2016; 4: 294–296.
    1. Carbone S, Arena R, Abbate A. Lack of benefit for liraglutide in heart failure. JAMA 2016; 316: 2429.
    1. Margulies KB, McNulty SE, Cappola TP. Lack of benefit for liraglutide in heart failure—reply. JAMA 2016; 316: 2429–2430.
    1. Rossignol P, Masson S, Barlera S, Girerd N, Castelnovo A, Zannad F, Clemenza F, Tognoni G, Anand IS, Cohn JN, Anker SD, Tavazzi L, Latini R. Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI‐HF and Val‐HeFT trials. Eur J Heart Fail 2015; 17: 424–433.
    1. Zamora E, Díez López C, Lupón J, de Antonio M, Domingo M, Santesmases J, Troya MI, Diez‐Quevedo C, Altimir S, Bayes‐Genis A. Weight loss in obese patients with heart failure. J Am Heart Assoc 2016; 5: e002468.
    1. Wohlfahrt P, Redfield MM, Lopez‐Jimenez F, Melenovsky V, Kane GC, Rodeheffer RJ, Borlaug BA. Impact of general and central adiposity on ventricular‐arterial aging in women and men. JACC Heart Fail 2014; 2: 489–499.
    1. Borlaug BA, Redfield MM, Melenovsky V, Kane GC, Karon BL, Jacobsen SJ, Rodehher RJ. Longitudinal changes in left ventricular stiffness: a community‐based study. Circ Heart Fail 2013; 6: 944–952.
    1. Zamora E, Lupón J, Enjuanes C, Pascual‐Figal D, de Antonio M, Domingo M, Comin‐colet J, Vila J, Penafiel J, Farre N, Alonso N, Santesmases J, Troya M, Bayés‐Genís A. No benefit from the obesity paradox for diabetic patients with heart failure. Eur J Heart Fail 2016; 18: 851–858.
    1. van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WHM. Effects of the once‐daily GLP‐1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non‐diabetic adults. Int J Obes (Lond) 2014; 38: 784–793.
    1. Kamiya K, Masuda T, Matsue Y, Inomata T, Hamazaki N, Matsuzawa R, Tanaka S, Nozaki K, Maekawa E, Noda C, Yamaoka‐Tojo M, Masunaga A, Izumi T, Ako J. Complementary role of arm circumference to body mass index in risk stratification in heart failure. JACC Heart Fail 2016; 4: 265–273.
    1. Aquilani R, Opasich C, Verri M, Boschi F, Febo O, Pasini E, Pastoris O. Is nutritional intake adequate in chronic heart failure patients? J Am Coll Cardiol 2003; 42: 1218–1223.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever